Clearing senescent astrocytes prevents Parkinson’s in mouse model of sporadic disease. Systemic clearing of senescent astrocytes prevents Parkinson’s neuropathology and associated symptoms in a mouse model of sporadic disease, the type implicated in 95% of human cases.
A mathematical algorithm that can reliably detect dyskinesia, the side effect from Parkinson’s treatment that causes involuntary jerking movements and muscle spasms, could hold the key to improving treatment and for patients with the disease.
Testing the level of caffeine in the blood may provide a simple way to aid the diagnosis of Parkinson’s disease, according to a study published in the January 3, 2018, online issue of Neurology®, the medical journal of the American Academy of Neurology.
A new study, published in Proceedings of the National Academy of Sciences (PNAS), sheds light on a mechanism underlying Parkinson’s disease and suggests that Tacrolimus — an existing drug that targets the toxic protein interaction explored in the study — could be used as a novel treatment.
NIH-funded mouse study suggests LRRK gene is needed for dopamine neuron health. A new study published in the journal Neuron sheds light on the normal function of LRRK2, the most common genetic cause for late-onset Parkinson’s disease. The study was supported by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.